Clinical trial · no report yet · Phase 3
SACHI
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
- NCT05015608 ↗
- Completed
- Hutchison Medipharma Limited
- 39 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 22 | |
| Podcasts | 9 | |
| YouTube | 7 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Savolitinib + Osimertinib; Pemetrexed + Cisplatin /Carboplatin
- Arms
- Savolitinib + Osimertinib · Experimental
- Pemetrexed combined with platinum · Active comparator
- Enrollment
- 216
- Primary outcomes
- PFS
- Sponsor
- Hutchison Medipharma Limited
- Start
- Nov 22, 2021
- Primary completion
- Aug 22, 2025
- Results posted
- No
- Registry record
- NCT05015608 · updated May 27, 2026
Publications
linked from the registry- Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, Li X, Sun L, Yu Y, Jin B, Yang L, Guo Y, Xu H, Yi T, Zeng A, Dong X, Chen J, Wang Z, Niu H, Cheng Y, Pan P, Deng P, Pan H, Min X, Bai J, Liu L, Zhang T, Li J, Fan S, Shi MM, Mok T, Su W; SACHI Study Group. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2026 Jan 24;407(10526):375-387. doi: 10.1016/S0140-6736(25)01811-2. Epub 2026 Jan 13. PubMed 41544643